The federal contract IDV award is a $1.38 billion Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with Grifols USA LLC, a global healthcare company specializing in plasma-derived medicines and pharmaceutical supplies. Under this IDV, Grifols holds a $107.5 million Blanket Purchase Agreement specifically for the supply of PROLASTIN-C, an alpha1-proteinase inhibitor drug used to treat alpha1-antitrypsin deficiency. Grifols also maintains multiple other significant IDVs with federal agencies, including over $13 million in annual indefinite delivery contracts with the Centers for Disease Control and Prevention (CDC) to supply a wide range of pediatric and adult vaccines. The task orders provided demonstrate Grifols' consistent role in delivering essential pharmaceutical products, including PROLASTIN-C, PROLASTIN, and other vaccines, to support the VA's healthcare programs for veterans as well as broader federal public health initiatives. These IDVs allow civilian agencies to efficiently procure vital pharmaceuticals through competitive task order procedures without repetitive solicitations.
The scope of the VA's FSS-61-IB contract with Grifols encompasses a broad range of pharmaceutical and drug products, enabling various government agencies to access Grifols' comprehensive portfolio of essential medicines. The task orders show Grifols fulfilling firm fixed-price delivery orders for PROLASTIN-C and other specialized drugs at locations across the country, supporting the healthcare needs of veterans under the VA's Veterans Health Administration. The contract and associated awards do not utilize any set-aside designations, reflecting Grifols' status as a large business capable of meeting substantial federal pharmaceutical requirements.
Generated 11/20/24, 9:04 AM